Receptor News and Research

RSS

New studies suggest ways to improve cancer care by inhibiting oncogenes, boosting tumor-suppressor activity

Two new studies by cancer scientists at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) suggest new approaches for treating cancer by inhibiting overactive cancer-promoting genes and by enhancing the activity of sluggish tumor-suppressor genes.

7 Oct 2015

Researchers study effect of immune tolerance on certain cancer risks

For a malignant tumor to form, cancer cells must evade the immune system's attack. Numerous studies have already shown that cancer spreads particularly aggressively if there is an unfavorable balance between suppressing and active immune cells in the tumor microenvironment. "But we didn't know whether this is a consequence of an aggressive tumor or rather its cause," says Rudolf Kaaks, epidemiologist at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ).

7 Oct 2015

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx immunohistochemistry companion diagnostic.

From Quest Diagnostics 7 Oct 2015

Study describes new genome screen that identifies partner molecules of cell-waste disposal proteins

Rhythmic expression of key genes is essential for maintaining proper timekeeping of the body's clock. In addition, rhythmic degradation of clockwork proteins is also crucial. However, surprisingly, researchers know little about these specific processes.

7 Oct 2015

Researchers explore how common genetic mutation influences effects of taking melatonin close to mealtime

Researchers from Brigham and Women's Hospital and the University of Murcia, Spain, have shed new light on why people who carry a common genetic mutation may be more at risk for developing type 2 diabetes. By carefully studying healthy subjects, researchers were able to chart the effect of melatonin supplements on blood sugar control.

7 Oct 2015

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

Clinical trial results suggest significant benefits with the use of cabozantinib or nivolumab over everolimus for patients with advanced renal cell carcinoma, researchers reported at the European Cancer Congress in Vienna, Austria.

6 Oct 2015

Dopamine transmission mediated by D1 receptors essential for controlling movements in Parkinson's disease

Dopamine deficiency in the basal ganglia (a set of subcortical structures) causes severe motor dysfunctions, such as slowness of movements (bradykinesia), as observed in Parkinson's disease. Dopamine binds D1 and D2 receptors that are expressed in the nerve cells of the striatum (a structure of the basal ganglia), and exerts different effects on the nerve cells. However, how dopamine controls through these receptors the information flow in the basal ganglia and voluntary movements is still not clear.

6 Oct 2015

IU-led scientists discover new gene that increases Alzheimer's disease risk

In a newly published study, a multi-institutional team led by scientists at the Indiana University School of Medicine have discovered an immune system gene associated with higher rates of amyloid plaque buildup in the brains of Alzheimer's patients and older adults at risk for the disease.

6 Oct 2015

UT Southwestern announces launch of new health initiative

UT Southwestern Medical Center today announced the launch of "Call Out Cancer," a new health initiative designed to promote awareness, early detection, and prevention of all types of cancer.

6 Oct 2015

Key neurotransmitter receptor may be a potential target for individualised Autism Spectrum Disorder treatment

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have uncovered a significant—and potentially treatable—relationship between a chemical that helps transmit signals in the brain and genetic mutations present in a subset of individuals with autism spectrum disorder.

5 Oct 2015

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers and published online today in the New England Journal of Medicine.

1 Oct 2015

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer-related deaths among men in the U.S. The challenge with prostate cancer is that the standard treatment methods in the advanced stage of the disease lose effectiveness after about one to two years, leading to recurrence and, ultimately, death. A University of Houston researcher and his team are working to change that.

30 Sep 2015

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

30 Sep 2015

Saint Louis University receives NIH grant to investigate development of new drugs to treat bone diseases

David Griggs, Ph.D., director of biology at Saint Louis University's Center for World Health & Medicine, has received a $1 million R01 grant from the National Institutes of Health to investigate the development of what could be a new class of drugs to treat bone diseases.

30 Sep 2015

Study raises hope for reducing life-threatening respiratory problems in infants

St. Jude Children's Research Hospital scientists have a lead on reducing life-threatening respiratory problems in infants born to women who develop the liver disorder intrahepatic cholestasis of pregnancy (ICP).

30 Sep 2015

New gene therapy approach to treating DMD reduces symptoms, extends life span in mouse model

A gene therapy approach to treating the progressive muscle wasting disorder Duchenne muscular dystrophy (DMD) that does not replace the mutated DMD gene but instead delivers the gene for ITGA7, a protein in skeletal muscle, led to reduced symptoms and significantly extended life span in a mouse model of severe DMD. Over-expression of ITGA7 did not elicit an immune reaction, further supporting its potential as a novel treatment for DMD, according to a new study published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

30 Sep 2015

Serologic status and autoimmune cerebellar ataxia type predict treatment response

Patients with autoimmune cerebellar ataxia have better treatment responses and outcomes if they have the nonparaneoplastic form of the condition and are seropositive for neural plasma membrane protein or glutamic acid decarboxylase 65 antibodies, suggests research.

29 Sep 2015

Tailorx trial data supports use of Oncotype DX test in patients with early stage breast cancer

Initial results were announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early stage breast cancer sponsored by the National Cancer Institute, part of the National Institutes of Health, and led by the ECOG-ACRIN Cancer Research Group with support from Genomic Health, Inc.

29 Sep 2015

New drug works better than current treatments for advanced kidney cancer

A new drug has been found superior to current treatments in slowing the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute.

29 Sep 2015

Roche launches the cobas EGFR Mutation Test v2 for use with either plasma or tumour tissue samples

Roche has announced the commercial availability in countries that accept the CE mark1 of the cobas® EGFR Mutation Test v2, the first oncology assay from Roche that utilises either plasma or tumour tissue as a sample. The test identifies 42 mutations in the epidermal growth factor receptor (EGFR) gene, the most of any In-vitro Diagnostic (IVD) on the market, and can also be used as an aid in selecting eligible patients with non-small cell lung cancer (NSCLC) for therapy with an EGFR tyrosine kinase inhibitor (TKI).

From Roche Sequencing and Life Science 28 Sep 2015

Receptor News and Research

New studies suggest ways to improve cancer care by inhibiting oncogenes, boosting tumor-suppressor activity

Researchers study effect of immune tolerance on certain cancer risks

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Study describes new genome screen that identifies partner molecules of cell-waste disposal proteins

Researchers explore how common genetic mutation influences effects of taking melatonin close to mealtime

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

Dopamine transmission mediated by D1 receptors essential for controlling movements in Parkinson's disease

IU-led scientists discover new gene that increases Alzheimer's disease risk

UT Southwestern announces launch of new health initiative

Key neurotransmitter receptor may be a potential target for individualised Autism Spectrum Disorder treatment

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Saint Louis University receives NIH grant to investigate development of new drugs to treat bone diseases

Study raises hope for reducing life-threatening respiratory problems in infants

New gene therapy approach to treating DMD reduces symptoms, extends life span in mouse model

Serologic status and autoimmune cerebellar ataxia type predict treatment response

Tailorx trial data supports use of Oncotype DX test in patients with early stage breast cancer

New drug works better than current treatments for advanced kidney cancer

Roche launches the cobas EGFR Mutation Test v2 for use with either plasma or tumour tissue samples

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News